Concourse Financial Group Securities, Inc. Editas Medicine, Inc. Transaction History
Concourse Financial Group Securities, Inc.
- $1.67 Billion
- Q4 2024
A detailed history of Concourse Financial Group Securities, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Concourse Financial Group Securities, Inc. holds 75 shares of EDIT stock, worth $103. This represents 0.0% of its overall portfolio holdings.
Number of Shares
75
Previous 75
-0.0%
Holding current value
$103
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding EDIT
# of Institutions
228Shares Held
54.7MCall Options Held
425KPut Options Held
306K-
Black Rock Inc. New York, NY7.78MShares$10.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.82MShares$9.42 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.75MShares$3.79 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.16MShares$2.98 Million0.0% of portfolio
-
State Street Corp Boston, MA1.87MShares$2.58 Million0.0% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $94.9M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...